Alternative pathway activation in sickle cell disease and beta-thalassemia major
- PMID: 702579
- PMCID: PMC2537184
Alternative pathway activation in sickle cell disease and beta-thalassemia major
Abstract
Total hemolytic complement activity (CH50), immuno-electrophoretic conversion of Factor B (C3PA), and of C3 were studied in 16 patients with sickle cell disease in a steady state, eight patients in crisis, and ten patients with β-thalassemia major anemia maintained on a constant transfusion regimen. Patients with sickle cell disease in a steady state have moderatley 56 (percent) depressed conversion of Factor B in addition to markedly decreased conversion of C3 in four of ten patients. One of the three sickle cell patients and two of the four thalassemia patients with low C3 conversion levels have died subsequent to the studies. The combination of chronically decreased Factor B conversion in the face of markedly decreased C3 conversion may make these patients occasionally vulnerable to overwhelming infection analagous to the situation seen in postsplenectomy cases.
Similar articles
-
[Complement and serum immunoglobulins in homozygous and heterozygous sickle cell anemia in Senegal].Dakar Med. 1999;44(2):175-9. Dakar Med. 1999. PMID: 11957280 French.
-
Plasma haemoglobin and complement activation in sickle cell disease.J Clin Lab Immunol. 1981 Jul;6(1):57-60. J Clin Lab Immunol. 1981. PMID: 7265176
-
Immunological studies in sickle cell-beta zero thalassemia. Comparison with sickle cell anemia.Haematologica. 1989 Nov-Dec;74(6):537-40. Haematologica. 1989. PMID: 2628234
-
Alternative complement pathway activity in sera from patients with sickle cell disease.Clin Exp Immunol. 1976 Jan;23(1):56-60. Clin Exp Immunol. 1976. PMID: 816581 Free PMC article.
-
Serum immunoglobulins in sickle cell disease.J Assoc Physicians India. 1993 Jul;41(7):418-9. J Assoc Physicians India. 1993. PMID: 8300484
Cited by
-
Development of complement therapeutics for inhibition of immune-mediated red cell destruction.Transfusion. 2005 Aug;45(2 Suppl):122S-9S. doi: 10.1111/j.1537-2995.2005.00526.x. Transfusion. 2005. PMID: 16086799 Free PMC article. Review.
-
Management of hemolytic transfusion reactions.Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):704-709. doi: 10.1182/hematology.2021000308. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889404 Free PMC article. Review.
-
Complement in Sickle Cell Disease: Are We Ready for Prime Time?J Blood Med. 2021 Mar 23;12:177-187. doi: 10.2147/JBM.S287301. eCollection 2021. J Blood Med. 2021. PMID: 33790681 Free PMC article. Review.
-
Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs.Front Immunol. 2020 Jun 30;11:1323. doi: 10.3389/fimmu.2020.01323. eCollection 2020. Front Immunol. 2020. PMID: 32695110 Free PMC article. Review.
-
Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.J Clin Invest. 1993 Sep;92(3):1326-35. doi: 10.1172/JCI116706. J Clin Invest. 1993. PMID: 7690777 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous